Investment Plan for Research and Production Facilities
First written in FY2016-Q2. 30 of 34 entries say "Advanced", first in FY2016-Q3. Latest entry: FY2026-H1.
126 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「Otsuka Pharmaceutical Co., Ltd. Mima Plant Mima, Tokushima Prefecture Healthcare business Production facilities 18,200 220 Internal funds 2026 2028 Otsuka Pharmaceutical Factory, Inc. Toyama Plant Imizu, Toyama Prefecture Healthcare business Production facilities 22,800 － Internal funds 2026 2030 Pharmavite LLC United States Nutraceuticals-related business Production facilities 17,382 115 Internal funds 2026 2028 Otsuka Clinical Nutrition America LLC United States Healthcare business Production facilities 84,668 1,402 Internal funds 2026 2033」
The company has developed detailed new construction plans for production facilities at the Mima Plant, Toyama Plant, Pharmavite and Otsuka Clinical Nutrition America, with construction scheduled to begin in 2026. - FY2025AdvancedAnnual report
「Otsuka Chemical Co., Ltd. Kawauchi-cho, Tokushima, Tokushima Prefecture Healthcare business Production facilities 12,772 316 Internal funds 2026 2027」
A new construction plan for production facilities in Kawauchi-cho, Tokushima, Tokushima Prefecture, has been newly disclosed, with a total investment of ¥12,772 million, construction starting in 2026 and completion scheduled for 2027. - FY2025-H1SoftenedAnnual report
「The company decided during the current interim consolidated accounting period to discontinue construction of the facilities below, which had been under construction at the end of the previous consolidated fiscal year.」
The company decided in May 2025 to discontinue the construction plan for Otsuka Warehouse's New East Japan Logistics Center. - FY2024AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥327,325 million.」
Capital expenditures totaled ¥327,325 million, including ¥252,004 million in the healthcare business and ¥54,170 million in the nutraceuticals-related business. The investments included the acquisition of Junana and investments in production and research facilities. - FY2024-H1AdvancedAnnual report
「Taiho Pharmaceutical Co., Ltd. Itano District, Tokushima Prefecture Kitajima Town Healthcare business Production facilities 18,000 － Internal funds 2024 2028」
A new construction plan for production facilities in Kitajima, Itano District, Tokushima Prefecture, has been finalized, with a total investment of ¥18,000 million, construction starting in 2024 and completion scheduled for 2028. - FY2024-Q1AdvancedAnnual report
「Cash flow from investing activities during the first quarter of the current consolidated cumulative period was negative ¥91,459 million, representing an increase of ¥55,687 million in cash outflows year on year. Major items included expenditures of ¥25,988 million for the acquisition of property, plant and equipment, ¥14,174 million for the acquisition of intangible assets, and ¥35,680 million for the acquisition of investments.」
The company continued investing for sustainable future growth, and expenditures for the acquisition of property, plant and equipment, intangible assets and investments increased from the same quarter of the previous year. The company also cited increased payments of contractual upfront fees and milestone payments in the healthcare business as a contributing factor. - FY2023AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥210,988 million.」
Capital expenditures increased from ¥139,319 million in the previous fiscal year to ¥210,988 million. Investments were made in the acquisition of Bonafide Health and in research and production facilities for the healthcare business. - FY2023-Q3AdvancedAnnual report
「Cambridge Isotope Laboratories, Inc. United States Massachusetts Healthcare business Office, production and research facilities 9,080 3,341 Internal funds 2023 2025 Otsuka Warehouse Co., Ltd. New East Japan Logistics Center Takasaki, Gunma Prefecture Other businesses Warehouse 13,800 7 Internal funds and intra-group financing 2025 2027」
A new construction plan has been finalized for an investment of ¥9,080 million in office, production and research facilities at Cambridge Isotope Laboratories and ¥13,800 million in the New East Japan Logistics Center. - FY2023-Q2AdvancedAnnual report
「Major items for the six months ended the second quarter included payments of ¥43,004 million for the acquisition of property, plant and equipment, proceeds of ¥12,143 million from the sale and redemption of investments, and payments of ¥21,750 million for the acquisition of investments.」
The company continued investing to support future sustainable growth, spending ¥43,004 million on the acquisition of property, plant and equipment and ¥21,750 million on the acquisition of investments. - FY2023-Q1AdvancedAnnual report
「Cash flow from investing activities for the three months ended the first quarter was ¥35,771 million, an increase of ¥12,974 million in cash outflows year on year. Major items included payments of ¥20,235 million for the acquisition of property, plant and equipment and ¥16,102 million for the acquisition of investments.」
The company continued investing to support future sustainable growth, and payments for the acquisition of property, plant and equipment and investments increased from the same quarter of the previous year. - FY2022AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥139,319 million.」
The company made capital expenditures of ¥139,319 million and advanced investments in the Otsuka Drug Discovery Research Center, the acquisition of intangible assets including TAS6417, and production equipment plans for PharmaVite. - FY2022-Q3AdvancedAnnual report
「PharmaVite LLC United States Ohio Nutraceuticals business Production equipment 34,319 284 Internal funds 2022 2024」
The company newly finalized plans to build production equipment for PharmaVite LLC in Ohio, USA, with total planned investment of ¥34,319 million, work beginning in 2022 and completion scheduled for 2024. - FY2022-Q2AdvancedAnnual report
「Cash flow from investing activities for the six months ended the second quarter was ¥56,031 million, an increase of ¥36,594 million in cash outflows year on year. Major items included payments of ¥30,666 million for the acquisition of property, plant and equipment, ¥38,894 million for the acquisition of intangible assets, including the acquisition of TAS6417 from Cullinan Pearl, proceeds of ¥29,522 million from the sale and redemption of investments, and payments of ¥13,183 million for the acquisition of investments.」
The company spent ¥30,666 million on the acquisition of property, plant and equipment and ¥38,894 million on the acquisition of intangible assets. It made investments in the healthcare business, including the acquisition of TAS6417 from Cullinan Pearl. - FY2021AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥144,109 million.」
The company made investments related to capital expenditures and research and development, including construction of the Osaka Drug Discovery Research Institute and the acquisition of intangible assets under co-development and distribution agreements. Work at the Osaka Drug Discovery Research Institute was scheduled to begin in 2021 and be completed in 2022, with ¥7,761 million already paid. - FY2021-Q3AdvancedAnnual report
「Otsuka Pharmaceutical Co., Ltd. Osaka Drug Discovery Research Institute Minoh, Osaka Prefecture Healthcare business Research equipment 15,950 7,761 Internal funds 2021 2022 EN Otsuka Pharmaceutical Co., Ltd. Hanamaki Plant Hanamaki, Iwate Prefecture Healthcare business Production equipment 5,050 242 Group financing and bank borrowings 2021 2022」
Amounts already paid for research equipment at the Osaka Drug Discovery Research Institute increased to ¥7,761 million, and ¥242 million was paid for production equipment investment at the Hanamaki Plant. The company continued its capital expenditure plans, including business facilities and other assets at the Tokushima Plant. - FY2021-Q2AdvancedAnnual report
「EN Otsuka Pharmaceutical Co., Ltd. Hanamaki Plant Hanamaki, Iwate Prefecture Healthcare business Production equipment 5,050 － Group financing and bank borrowings 2021 2022」
The company newly finalized a plan to build production equipment at the Hanamaki Plant, with total planned investment of ¥5,050 million, work beginning in 2021 and completion scheduled for 2022. Amounts already paid for research equipment at the Osaka Drug Discovery Research Institute increased from ¥122 million to ¥3,942 million. - FY2021-Q1AdvancedAnnual report
「Otsuka Chemical Tokushima Plant Tokushima, Tokushima Prefecture Corporate administration Business facilities and other assets 5,180 － Internal funds 2021 2024 Otsuka Pharmaceutical Co., Ltd. Osaka Drug Discovery Research Institute Minoh, Osaka Prefecture Healthcare business Research equipment 15,950 122 Internal funds 2021 2022」
The company newly finalized plans to build business facilities and other assets at Otsuka Chemical's Tokushima Plant for ¥5,180 million and research equipment at the Osaka Drug Discovery Research Institute for ¥15,950 million. Work at the Osaka Drug Discovery Research Institute was scheduled to begin in 2021 and be completed in 2022. - FY2020AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥122,797 million.」
The company made investments in production equipment at the Tokushima Mima Plant and elsewhere, as well as in intangible assets acquired under the Entresto co-promotion agreement. - FY2020-Q3AdvancedAnnual report
「Cash flow from investing activities for the nine months ended the third quarter was ¥86,688 million. Major items included payments of ¥36,754 million for the acquisition of property, plant and equipment, ¥39,803 million for the acquisition of intangible assets, including the upfront fee and other payments under the co-promotion agreement for “Entresto” in Japan, proceeds of ¥14,124 million from the sale and redemption of investments, and payments of ¥19,792 million for the acquisition of investments.」
The company acquired property, plant and equipment, intangible assets related to the Entresto co-promotion agreement, and investments, and continued investing to support future sustainable growth. - FY2020-Q2AdvancedAnnual report
「Cash flow from investing activities for the six months ended the second quarter was ¥60,232 million. Major items included payments of ¥26,517 million for the acquisition of property, plant and equipment, ¥27,033 million for the acquisition of intangible assets, including the upfront fee and other payments under the co-promotion agreement for “Entresto” in Japan, and ¥12,886 million for the acquisition of investments.」
To support future sustainable growth, the company made investments including the acquisition of property, plant and equipment and intangible assets. In the healthcare business, investments included the upfront fee under the co-promotion agreement for Entresto. - FY2020-Q1AdvancedAnnual report
「Payments for the acquisition of property, plant and equipment were ¥12,710 million, payments for the acquisition of intangible assets were ¥17,434 million, including the upfront fee under the co-promotion agreement for “LCZ696” in Japan (generic name: sacubitril valsartan sodium hydrate), and payments for the acquisition of investments were ¥5,440 million, among others.」
During the first quarter, the company made investments including ¥12,710 million for the acquisition of property, plant and equipment and ¥17,434 million for the acquisition of intangible assets. The acquisition of intangible assets included the upfront fee under the co-promotion agreement for LCZ696 in Japan. - FY2019AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥87,133 million. These investments were funded with internal funds and borrowings.」
The company made capital expenditures at the Tokushima Mima and Matsushige plants and Daiya Foods' Burnaby Plant, among others. As of the end of the fiscal year, plans to build and renovate the Tokushima Mima Plant, Burnaby Plant and Tokyo Headquarters remained ongoing. - FY2019-Q3AdvancedAnnual report
「With investments in production equipment at the Tokushima Mima and Matsushige plants and other investments in the healthcare business to support future sustainable growth, cash flow used in investing activities was ¥58,676 million.」
The company made investments in production equipment at the Tokushima Mima and Matsushige plants. - FY2018AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥193,782 million.」
Capital expenditures increased from ¥152,257 million in the previous fiscal year to ¥193,782 million. In addition to investments in goodwill and intangible assets related to the acquisitions of Riko Medical and BESTERRA, the company continued production equipment plans for the Tokushima, Tokushima Mima and Matsushige plants. - FY2018-Q3RestatedAnnual report
「Otsuka Pharmaceutical Co., Ltd. Tokushima Plant and other facilities Tokushima, Tokushima Prefecture, and other locations Healthcare business Production equipment (manufacturing support system) 3,532 155 Internal funds 2018 2021」
The company continued its plans for manufacturing support systems at the Tokushima Plant and other facilities and production equipment at the Matsushige Plant. Planned investment at the Matsushige Plant was ¥7,500 million, with ¥2,058 million already paid. - FY2018-Q2SoftenedAnnual report
「Otsuka Pharmaceutical Factory, Inc. Matsushige Plant Matsushige, Tokushima Prefecture Healthcare business Production equipment 7,500 1,864 Internal funds and borrowings 2018 2019」
Planned investment at the Matsushige Plant decreased from the ¥7,941 million previously disclosed to ¥7,500 million. The manufacturing support system plan for the Tokushima Plant and other facilities continued. - FY2018-Q1AdvancedAnnual report
「Otsuka Pharmaceutical Co., Ltd. Tokushima Plant and other facilities Tokushima, Tokushima Prefecture, and other locations Healthcare business Production equipment (manufacturing support system) 3,532 162 Internal funds 2018 2021」
The company newly finalized a capital expenditure plan for manufacturing support systems at the Tokushima Plant and other facilities, with planned investment of ¥3,532 million, ¥162 million already paid, work beginning in 2018 and completion scheduled for 2021. It also disclosed a plan for ¥7,941 million of production equipment at the Matsushige Plant, with work beginning in 2018 and completion scheduled for 2019. - FY2017AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥152,257 million.」
The company made full-year capital expenditures of ¥152,257 million, including investments in goodwill and intangible assets related to the acquisitions of NeuroVance and Daiya Foods. Equipment plans for the Tokushima Mima Plant and other facilities also continued. - FY2017-Q3AdvancedAnnual report
「Otsuka Pharmaceutical Co., Ltd. Tokushima Mima Plant Mima, Tokushima Prefecture Healthcare business Production equipment 9,928 3,036 Internal funds 2017 2018」
The company updated the planned investment and amounts already paid for the Tokushima Mima Plant, Akō No. 3 Warehouse and Tokyo Headquarters Building. Planned investment for the Tokushima Mima Plant was ¥9,928 million, with ¥3,036 million already paid. - FY2017-Q2AdvancedAnnual report
「Otsuka Pharmaceutical Co., Ltd. Tokushima Mima Plant Mima, Tokushima Prefecture Healthcare business Production equipment 8,838 2,652 Internal funds 2017 2018」
The company updated the planned investment and amounts already paid for the Tokushima Mima Plant, Akō No. 3 Warehouse and Tokyo Headquarters Building. The amount already paid for the Tokushima Mima Plant was ¥2,652 million. - FY2017-Q1AdvancedAnnual report
「Otsuka Pharmaceutical Co., Ltd. Tokushima Mima Plant Healthcare business Production equipment 8,838 440 Internal funds 2017 2018」
The company newly finalized plans to build production equipment at the Tokushima Mima Plant for ¥8,838 million, the Akō No. 3 Warehouse for ¥2,532 million, and the Tokyo Headquarters Building for ¥2,376 million. - FY2016AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year, including investments in goodwill and intangible assets, totaled ¥75,457 million.」
The company made full-year capital expenditures of ¥75,457 million, including ¥52,163 million in the healthcare business and ¥11,562 million in the nutraceuticals business, and disclosed plans for new facilities to be built between 2017 and 2019. - FY2016-Q3AdvancedAnnual report
「Nutrition et Nature SAS Compiègne Plant France Picardy Nutraceuticals business Production equipment 2,267 542 Internal funds 2016 2017」
For the Compiègne Plant production equipment investment, the company disclosed a total planned investment of ¥2,267 million and ¥542 million already paid. - FY2016-Q2First statedAnnual report
「大鵬薬品工業㈱ Saitama Plant K児玉郡, Saitama Prefecture Healthcare business Research equipment 6,800 0 Internal funds 2016 2019」
The company disclosed plans to invest ¥6,800 million in research equipment at the Saitama Plant and ¥2,287 million in production equipment at the Compiègne Plant in France.